Wird geladen...
Platinum-containing compound platinum pyrithione is stronger and safer than cisplatin in cancer therapy
DNA is the well-known molecular target of current platinum-based anticancer drugs; consequently, their clinical use is severely restricted by their systemic toxicities and drug resistance originating from non-selective DNA damage. Various strategies have been developed to circumvent the shortcomings...
Gespeichert in:
| Veröffentlicht in: | Biochem Pharmacol |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5287571/ https://ncbi.nlm.nih.gov/pubmed/27381943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2016.06.019 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|